138 related articles for article (PubMed ID: 9935012)
41. Frequency and predictors of stent thrombosis after percutaneous coronary intervention in acute myocardial infarction.
Dangas GD; Caixeta A; Mehran R; Parise H; Lansky AJ; Cristea E; Brodie BR; Witzenbichler B; Guagliumi G; Peruga JZ; Dudek D; Möeckel M; Stone GW;
Circulation; 2011 Apr; 123(16):1745-56. PubMed ID: 21482968
[TBL] [Abstract][Full Text] [Related]
42. Safe and efficacious use of bivalirudin for percutaneous coronary intervention with adjunctive platelet glycoprotein IIb/IIIa receptor inhibition.
Cho L; Chew DP; Moliterno DJ; Roffi M; Ellis SG; Franco I; Bajzer C; Bhatt DL; Dorosti K; Simpfendorder C; Tuzcu M; Yadav JS; Brener S; Raymond R; Whitlow P; Topol EJ; Lincoff AM
Am J Cardiol; 2003 Mar; 91(6):742-3. PubMed ID: 12633814
[No Abstract] [Full Text] [Related]
43. Evolution of improved antithrombotic and antiplatelet agents: genesis of the Comparison of Abciximab Complications with Hirulog [and back-Up Abciximab] Events Trial (CACHET).
Topol EJ
Am J Cardiol; 1998 Oct; 82(8B):63P-68P. PubMed ID: 9809894
[TBL] [Abstract][Full Text] [Related]
44. Bivalirudin during percutaneous coronary interventions in patients with ST segment elevation myocardial infarction.
Koutouzis M; Albertsson P
Acute Card Care; 2010 Jun; 12(2):75-6. PubMed ID: 20384472
[TBL] [Abstract][Full Text] [Related]
45. Low-molecular-weight heparin and other antithrombotic agents in the setting of a fast-track revascularization in unstable coronary artery disease.
Bassand JP
Haemostasis; 2000; 30 Suppl 2():114-21; discussion 106-7. PubMed ID: 11251354
[TBL] [Abstract][Full Text] [Related]
46. The changing horizon of acute coronary syndrome.
de Silva R; Fox KM
Lancet; 2009 Oct; 374(9696):1125-7. PubMed ID: 19717183
[No Abstract] [Full Text] [Related]
47. Anticoagulation with bivalirudin during percutaneous coronary intervention for ST-segment elevation myocardial infarction.
Stella JF; Stella RE; Iaffaldano RA; Stella DJ; Erickson KW; Bliley RC
J Invasive Cardiol; 2004 Sep; 16(9):451-4. PubMed ID: 15353822
[TBL] [Abstract][Full Text] [Related]
48. Overcoming heparin limitations in high-risk percutaneous coronary intervention: the alternative strategy-- replacing heparin with bivalirudin.
Henry TD
J Invasive Cardiol; 2002 Apr; 14 Suppl B():19B-29B. PubMed ID: 11967387
[No Abstract] [Full Text] [Related]
49. Effect of bivalirudin compared with unfractionated heparin plus abciximab on infarct size and myocardial recovery after primary percutaneous coronary intervention: the horizons-AMI CMRI substudy.
Wöhrle J; Merkle N; Kunze M; Cristea E; Mehran R; Rottbauer W; Stone GW
Catheter Cardiovasc Interv; 2012 Jun; 79(7):1083-9. PubMed ID: 22162175
[TBL] [Abstract][Full Text] [Related]
50. Absolute and relative truth in clinical trials.
Julian D
Lancet; 2002 Jun; 359(9321):1945-6; author reply 1946. PubMed ID: 12057577
[No Abstract] [Full Text] [Related]
51. Direct thrombin inhibitors for non-ST-segment elevation acute coronary syndromes: what, when, and where?
Lincoff AM
Am Heart J; 2003 Oct; 146(4 Suppl):S23-30. PubMed ID: 14564303
[TBL] [Abstract][Full Text] [Related]
52. Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET).
Lincoff AM; Kleiman NS; Kottke-Marchant K; Maierson ES; Maresh K; Wolski KE; Topol EJ
Am Heart J; 2002 May; 143(5):847-53. PubMed ID: 12040347
[TBL] [Abstract][Full Text] [Related]
53. Bivalirudin during primary PCI in acute myocardial infarction.
Stone GW; Witzenbichler B; Guagliumi G; Peruga JZ; Brodie BR; Dudek D; Kornowski R; Hartmann F; Gersh BJ; Pocock SJ; Dangas G; Wong SC; Kirtane AJ; Parise H; Mehran R;
N Engl J Med; 2008 May; 358(21):2218-30. PubMed ID: 18499566
[TBL] [Abstract][Full Text] [Related]
54. Follow the data: bivalirudin (and not heparin alone) during percutaneous coronary intervention provides the best clinical outcomes.
Stone GW; Mehran R; Steg PG
JACC Cardiovasc Interv; 2015 Jan; 8(1 Pt B):225-227. PubMed ID: 25616930
[No Abstract] [Full Text] [Related]
55. Prognostic value of a high on-clopidogrel treatment platelet reactivity in bivalirudin versus abciximab treated non-ST-segment elevation myocardial infarction patients. ISAR-REACT 4 (Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment-4) platelet substudy.
Sibbing D; Bernlochner I; Schulz S; Massberg S; Schömig A; Mehilli J; Kastrati A
J Am Coll Cardiol; 2012 Jul; 60(5):369-77. PubMed ID: 22682553
[TBL] [Abstract][Full Text] [Related]
56. HORIZONS trial: a step forward for primary percutaneous coronary intervention.
White HD
Expert Rev Cardiovasc Ther; 2009 Feb; 7(2):125-9. PubMed ID: 19210208
[TBL] [Abstract][Full Text] [Related]
57. A second look at bivalirudin.
Antman EM; Braunwald E
Am Heart J; 2001 Dec; 142(6):929-31. PubMed ID: 11717592
[No Abstract] [Full Text] [Related]
58. Clinical trials of Hirulog in patients undergoing high-risk percutaneous transluminal coronary angioplasty.
Bittl JA
Coron Artery Dis; 1996 Jun; 7(6):449-54. PubMed ID: 8889360
[No Abstract] [Full Text] [Related]
59. Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial.
Mehran R; Lansky AJ; Witzenbichler B; Guagliumi G; Peruga JZ; Brodie BR; Dudek D; Kornowski R; Hartmann F; Gersh BJ; Pocock SJ; Wong SC; Nikolsky E; Gambone L; Vandertie L; Parise H; Dangas GD; Stone GW;
Lancet; 2009 Oct; 374(9696):1149-59. PubMed ID: 19717185
[TBL] [Abstract][Full Text] [Related]
60. Effect of direct thrombin inhibition with Bivalirudin (Hirulog) on restenosis after coronary angioplasty.
Burchenal JE; Marks DS; Tift Mann J; Schweiger MJ; Rothman MT; Ganz P; Adelman B; Bittl JA
Am J Cardiol; 1998 Aug; 82(4):511-5. PubMed ID: 9723642
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
